[go: up one dir, main page]

ATE397673T1 - ENHANCED CANCER GENE WIP1 - Google Patents

ENHANCED CANCER GENE WIP1

Info

Publication number
ATE397673T1
ATE397673T1 AT02723130T AT02723130T ATE397673T1 AT E397673 T1 ATE397673 T1 AT E397673T1 AT 02723130 T AT02723130 T AT 02723130T AT 02723130 T AT02723130 T AT 02723130T AT E397673 T1 ATE397673 T1 AT E397673T1
Authority
AT
Austria
Prior art keywords
wip1
cancer gene
prevention
enhanced cancer
diagnosis
Prior art date
Application number
AT02723130T
Other languages
German (de)
Inventor
Jing Li
Scott Powers
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE397673T1 publication Critical patent/ATE397673T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the WIP1 gene, which are amplified breast, and/or lung, and/or colon, and/or ovarian, and/or prostate cancer genes. The WIP1 gene, its expressed protein products and antibodies are used diagnostically or as targets for cancer therapy; they are also used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
AT02723130T 2001-02-14 2002-02-12 ENHANCED CANCER GENE WIP1 ATE397673T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26836201P 2001-02-14 2001-02-14

Publications (1)

Publication Number Publication Date
ATE397673T1 true ATE397673T1 (en) 2008-06-15

Family

ID=23022645

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02723130T ATE397673T1 (en) 2001-02-14 2002-02-12 ENHANCED CANCER GENE WIP1

Country Status (6)

Country Link
US (1) US20030032027A1 (en)
EP (1) EP1370693B1 (en)
AT (1) ATE397673T1 (en)
CA (1) CA2438420A1 (en)
DE (1) DE60226956D1 (en)
WO (1) WO2002064838A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037360A1 (en) * 2002-03-22 2005-02-17 Government Of The United States Of America Materials and methods for inhibiting wip1
US20050026194A1 (en) * 2003-06-20 2005-02-03 Tularik Inc. Gene amplification and overexpression in cancer
US9040491B2 (en) * 2006-08-30 2015-05-26 The Trustees Of The University Of Pennsylvania Compositions, methods and kits based on small nuclear RNAs
US8740762B2 (en) * 2007-04-05 2014-06-03 Vanderbilt University Specific inhibition of cPLA2 enhances the efficacy of radiotherapy
US20100256098A1 (en) * 2007-08-31 2010-10-07 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
GB201220924D0 (en) * 2012-11-21 2013-01-02 Cancer Res Inst Royal Materials and methods for determining susceptibility or predisposition to cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5516663A (en) * 1990-01-26 1996-05-14 Abbott Laboratories Ligase chain reaction with endonuclease IV correction and contamination control
DK1068528T3 (en) * 1998-02-25 2006-11-27 Us Health Method and apparatus for preparing a set for rapid molecular profiling
US6232068B1 (en) * 1999-01-22 2001-05-15 Rosetta Inpharmatics, Inc. Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies

Also Published As

Publication number Publication date
WO2002064838A3 (en) 2003-10-16
CA2438420A1 (en) 2002-08-22
WO2002064838A2 (en) 2002-08-22
US20030032027A1 (en) 2003-02-13
EP1370693B1 (en) 2008-06-04
EP1370693A2 (en) 2003-12-17
DE60226956D1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2003079982A3 (en) Gene amplification in cancer
WO2008008315A3 (en) Compositions and methods for inhibiting growth of smad4-deficient cancers
WO2004046332A3 (en) Amplified genes involved in cancer
WO2002064839A3 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
ATE538215T1 (en) EXPRESSION PROFILE OF PROSTATE CARCINOMA
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
TR200102191T2 (en) HER-2 / neu fusion proteins.
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
MXPA03000527A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer.
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
EP1468014A4 (en) Compositions and methods for wt1 specific immunotherapy
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
WO2002071928A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003100000A3 (en) Amplification and overexpression of oncogenes
UA99602C2 (en) Antibody that specifically binds to jam-a, capable of inhibiting the proliferation of tumor cells
WO2003044161A3 (en) Gene amplification and overexpression in cancer
WO2003064593A3 (en) Antigen panels and methods of using the same
MX2009001014A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63.
EP1377596A4 (en) Ttk in diagnosis and as a therapeutic target in cancer
ATE397673T1 (en) ENHANCED CANCER GENE WIP1
WO2003054512A3 (en) Identification of an amplified gene and target for drug intervention

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties